The National Institute of Neurological Disorders and Stroke (NINDS) is launching a large phase 3 clinical trial to determine whether the nutritional supplement creatine can slow the progression of Parkinson disease.
The double-blind, placebo-controlled trial will enroll 1720 individuals with early-stage Parkinson disease at 51 medical centers in North America. Patients participating in the trial will be randomly assigned to receive either creatine or placebo for 5 to 7 years.
Kuehn BM. Creatine for Parkinson. JAMA. 2007;297(16):1764. doi:10.1001/jama.297.16.1764-b